President and Chief Executive Officer
Sam Rasty brings more than 20 years of experience in biopharma R&D, commercial, business development, strategy and operations in leadership roles of increasing responsibility spanning global large pharma, mid-cap pharma and early stage, private biotech companies. Most recently, he served as Chief Operating Officer at Homology Medicines, a genetic medicines company that he helped launch in 2016, having played a key role in transforming the company from a private start-up to an established, fully integrated public gene therapy and gene editing company. Prior to joining Homology as one of its early employees, he was Vice President and Head of New Products at the Rare Disease Business Unit of Shire Pharmaceuticals. His earlier career included roles spanning corporate development at Endo Pharmaceuticals and commercial strategy and portfolio management at GlaxoSmithKline. He received a Ph.D. in Biochemistry from Louisiana State University, completed his postdoctoral fellowship in Molecular Genetics and Biochemistry at the University of Pittsburgh School of Medicine and holds an MBA from Villanova University.